NCCN guidelines indicate rusfertide for patients who are intolerant to phlebotomy or who receive frequent phlebotomy, regardless of risk status.
|Videos|April 22, 2019
Polycythemia Vera
Polycythemia Vera
Advertisement
Case: 75-Year-Old Man Diagnosed With Polycythemia Vera
January 2018
- A 75-year old man presents to PCP for routine evaluation; feels well but complains of pruritus exacerbated by hot showers
- PE: Unremarkable
- PMH: No prior history of thrombosis, hypertension managed with statin
- Lab values:
- HGB: 18.9 g/dL
- Hct: .56 L/L
- RBC: 68 x 1012/L
- WBC: 10.6 x 109/L
- Serum EPO: 4.1 mU/mL
- Bone Marrow biopsy declined
- Cytogenetics: JAK-V617Fmutation
Advertisement
Related to this article
The FDA designation is for LYT-200 plus a hypomethylating agent for relapsed/refractory high-risk myelodysplastic syndromes.
The application for bezuclastinib in advanced systemic mastocytosisis is supported by data from the APEX trial.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
IMS Day 1 Recap: Bispecific and CAR T Data Shape Myeloma Treatment
2
What to Watch at IMS 2026: Defining Cure as Multitargeting, CELMoDs, and In Vivo CAR T Move Forward
3
Tovecimig Submission for Biliary Tract Cancer Is Proceeding Despite FDA Request for New Trial
4
Rusfertide Receives NCCN Category 1 Designation in Polycythemia Vera
5